Methodology breakdown computing — it will appear here on its own.
Olema Pharmaceuticals Inc (OLMA) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computing the full ratio and business-activity breakdown for OLMA — this runs off the critical path so the page paints first. It will appear here on its own.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Stanley Druckenmiller | Duquesne Family Office | $12M | 0.2% | 2026-06-30 |
| Ken Fisher | Fisher Asset Management | $4M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.90 | NEUTRAL |
| Stochastic %K (14) | 12.25 | BUY |
| CCI (20) | -110.82 | BUY |
| Williams %R (14) | -87.75 | BUY |
| MACD (12,26,9) | 0.00 | BUY |
| ROC (10) | -5.28 | SELL |
| Momentum (10) | -0.57 | SELL |
| EMA (10) | 10.60 | SELL |
| SMA (10) | 10.58 | SELL |
| EMA (20) | 10.74 | SELL |
| SMA (20) | 10.69 | SELL |
| EMA (30) | 10.88 | SELL |
| SMA (30) | 10.90 | SELL |
| EMA (50) | 11.21 | SELL |
| SMA (50) | 11.28 | SELL |
| EMA (100) | 12.32 | SELL |
| SMA (100) | 11.99 | SELL |
| EMA (200) | 14.80 | SELL |
| SMA (200) | 17.53 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Background via Yahoo Finance — informational, not part of the verdict.
No real edge — avoid
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 43 |
| ⏰ 4H | BEARISH | 38 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.